Context Therapeutics, Inc. ((CNTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Context Therapeutics, Inc. is conducting a Phase 1a/1b study titled ‘CT-95 in Advanced Cancers Associated With Mesothelin Expression.’ The study aims to assess the safety and efficacy of CT-95, a humanized T cell engaging bispecific antibody, in treating advanced solid tumors with Mesothelin expression. This research is significant as it targets a range of challenging cancers, potentially offering new treatment avenues.
The intervention being tested is CT-95, a drug administered through weekly intravenous dosing. It is designed to engage T cells to target Mesothelin-expressing tumors, which are prevalent in several advanced cancer types.
The study follows an interventional design with a single-group assignment. There is no masking involved, meaning all participants and researchers know the treatment being administered. The primary purpose is treatment-focused, aiming to explore the drug’s therapeutic potential.
The study began on December 18, 2024, with the latest update submitted on July 29, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status, which is vital for tracking its development and potential market entry.
For investors, this study update could influence Context Therapeutics’ stock performance positively, given the potential breakthrough in treating Mesothelin-expressing cancers. The competitive landscape includes other companies targeting similar pathways, but successful results could position Context Therapeutics favorably in the oncology market.
The study is currently recruiting, with further details accessible on the ClinicalTrials portal.